



AVICANNA™

Avicanna.com


January 2020

TSX: AVCN

OTCQX: AVCNF

FSE: ONN

Forward-Looking Statement



This document and the material contained herein are confidential and are not to be disclosed to the public. This is for information purposes only and may not be reproduced or distributed to any other person or published, in whole or part, for any purpose whatsoever. Certain information contained herein and certain oral statements made are forward-looking and relate to Avicanna Inc.'s ("Avicanna") business strategy, product development, timing of product development, events and courses of action. Statements which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, outlook, expectations or intentions regarding the future including words or phrases such as "anticipate," "objective," "may," "will," "might," "should," "could," "can," "intend," "expect," "believe," "estimate," "predict," "potential," "plan," "is designed to" or similar expressions suggest future outcomes or the negative thereof or similar variations. Forward-looking statements may include, among other things, statements about anticipated dates for revenue recognition; anticipated dates for product launches; our plans for future products and enhancements of existing products; designs for future product packaging; expected completion dates for clinical trials and product development; expected results of clinical trials; our future growth strategy; our future intellectual property, research and development, product formulations and business lines; intended quality standards of our joint venture with Sigma Analytics; each of our expected upcoming milestones; and our anticipated trends and challenges in the markets in which we operate. Such statements and information are based on numerous assumptions regarding present and future business strategies and the environment in which Avicanna will operate in the future, including the demand for our products, anticipated costs and ability to achieve goals, expected outcomes for clinical trials, the timely completion of research and development initiatives and the price of cannabis and cannabis related products. Although we believe that the assumptions underlying these statements are reasonable, they may prove to be incorrect.

Given these risks, uncertainties and assumptions, you should not place undue reliance on these forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties and other important factors that may cause the actual results to be materially different from those expressed or implied by such forward-looking statements, including but not limited to, business, economic and capital market conditions; the ability to manage our operating expenses, which may adversely impact our financial condition; our ability to remain competitive as other better financed competitors develop and release competitive products; regulatory uncertainties; weather patterns; market conditions and the demand and pricing for our products; the demand and pricing of cannabis and cannabidiol ("CBD"); security threats, including a loss/ theft of proprietary technology; our relationships with regulatory bodies, our customers, distributors and business partners; our ability to successfully define, design and release new products in a timely manner that meet our customers' needs; our ability to attract, retain and motivate qualified personnel; competition in our industry; our ability to maintain technological leadership; the impact of technology changes on our products and industry; our failure to develop new and innovative products; our ability to successfully maintain and enforce our intellectual property rights and defend third-party claims of infringement of their intellectual property rights; the impact of intellectual property litigation that could materially and adversely affect our business; our ability to manage working capital; our dependence on key personnel and additional risk factors included under the heading "Risk Factors" in Avicanna's long-form prospectus dated July 8, 2019. Avicanna is an early stage company with a short operating history; and it may not actually achieve its plans, projections, or expectations. Important factors that could cause actual results to differ materially from Avicanna's expectations include, consumer sentiment towards Avicanna's products and cannabis and cannabis related technology generally, litigation, global economic climate, equipment failures, increase in operating costs, decrease in the price of cannabis and CBD, security threats including a loss or theft of intellectual property, adverse medical findings, government regulations, loss of key employees and consultants, additional funding requirements, changes in laws, technology failures, competition, failure of counter-parties to perform their contractual obligations, delays or unexpected expenditures in completion of clinical trials, and unexpected delays in the commercialization of products. Except as required by law, we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future event or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. Neither we nor any of our representatives make any representation or warranty, express or implied, as to the accuracy, sufficiency or completeness of the information in this presentation. Neither we nor any of our representatives shall have any liability whatsoever, under contract, tort, trust or otherwise, to you or any person resulting from the use of the information in this presentation by you or any of your representatives or for omissions from the information in this presentation.

Financial & Third Party Information

All financial information included in this document is unaudited. There is a material risk that the audited financial results will differ significantly from the unaudited financial information presented herein. Avicanna disclaims any intention or obligation to update or revise any forward-looking statements contained in this document, whether as a result of new information, future events or otherwise, unless required pursuant to applicable securities law. Readers are cautioned that the forward-looking statements contained in this document should not be used for purposes other than for which it is disclosed herein. The forward-looking statements contained in this document are expressly qualified by this cautionary statement. Certain information contained herein is based on, or derived from, information provided by independent third-party sources. Avicanna believes that such information is accurate and that the sources from which it has been obtained are reliable. Avicanna cannot guarantee the accuracy of such information, however, and has not independently verified the assumptions on which such information is based. Avicanna does not assume any responsibility for the accuracy or completeness of such information.

Avicanna is a global leader in natural cannabinoid solutions developed through an evidence-based biopharmaceutical approach and offered across several product lines including cosmetics, medical and pharmaceuticals.

The Company ensures the safety and quality standards of its products through a vertically integrated business model, including robust cultivation, extraction, manufacturing, commercialization, R&D and clinical capabilities.



AVICANNA

Corporate Overview

Developing Cannabinoid Products Through Science



- A biopharmaceutical company developing, manufacturing and commercializing various cannabinoid-based products for the global market place, including retail, Rx and medical products, as well as cannabinoids as active pharmaceutical ingredients (API).



- Multi-national team of 20+ scientists and clinicians in four laboratories developing scientifically sound, quality tested organic hemp derived cannabinoid products.



- USDA organic certified hemp (non-psychoactive cannabis) derived products to the U.S., UK and South Africa in Q4 2019.



- Current annual cultivation capacity of approximately 20,000 kilograms through 410,000 square feet of cultivation space.



- Initiated commercial sales in Q4 2019 – including Pura Earth, a derma-cosmetics line of CBD-based products.

Increasing Number of Global Market Opportunities



- UK: GW Pharmaceutical's Epidiolex: Only pharmaceutical-grade CBD product currently approved by the United States FDA.
- US: 2018 Farm bill will allow federal level R&D and clinical development of CBD products under specific circumstances.
- EU: 2019 European Parliament passes resolution (2018/2775(RSP)) to advance use of cannabis for medicinal purposes.

Legal Cannabis Market Size 2018-2025

Geography/type	2018 (USD billion)	2025 (USD billion)	Growth 2018-25 (% value)	% share of total* 2018	% share of total* 2025
World legal & illicit total	150	214	43	n/a	n/a
World legal	12	166	1,283	8	77
US legal	10	60	500	20	90
Canada legal	1.4	6	330	20	90
Europe legal	0.5	80	15,900	1	80
Rest of world legal	0.1	20	19,900	0.2	50

Source: Euromonitor International estimates based on individual market readiness and current growth

Note: * Refers to the share of legal as a proportion of total market, i.e. legal plus illicit. Value sales = RSP.

Global Cannabis Industry Segments



Medical Cannabis: Plant-derived whole plant cannabis products supported by a health care practitioner for the treatment of specific conditions or diseases (eg, epilepsy, pain, multiple sclerosis). Non-pharmaceutical ingredients, limited pharmacology, regulatory and stability requirements.



Pharmaceutical cannabis: Products formulated using pure cannabinoids (either plant extracted or synthetic) that have been through full clinical trials and registration with the relevant drug authorities. Examples of products include Sativex, Epidiolex, Cesamet, Marinol and Syndros.



Recreational cannabis: Ordinarily has a higher concentration of THC, the psychoactive properties of the cannabis plant. People tend to smoke or ingest cannabis or use oils and vaporized products.



CBD infused products: Consumer goods, cosmetics, capsules and oils. Although these products may be used for wellness purposes such as to aid sleep, or for pain or anxiety management, they do not require a prescription.

Cannabis Industry: Risks and Concerns

Avicanna's business model addresses these concerns



1

Inefficient cultivation operations with heavy capital investments leading to uncompetitive practices

2

Environmentally unsustainable cultivation practices

3

Lack of investment into research and clinical development

4

Limited options and low sophistication of product offerings

5

Lack of separation between medical and recreational products

6

Public health concerns around safety and quality controls

Global Leader in Advanced Cannabinoid Research and Pharmaceutical Development



Experienced and Multi-national Team Of 20+ Scientists And Clinicians

Laboratories in Toronto, Canada & Bogota, and Santa Marta, Colombia



R&D Headquarters at the MaRS Discovery District

Cannabis Research Licence issued by Health Canada to Avicanna at JLABS @ Toronto located in the MaRS Discovery District, the world's largest urban innovation hub, where Avicanna's scientists conduct research in collaboration with world-class researchers, academic, and clinical institutions



Exclusive Collaboration Agreement with Dr. Christine Allen's Research Group ("CARG") at the University of Toronto

Cannabis Research Licence issued by Health Canada to Dr. Christine Allen's laboratory at the Leslie Dan Faculty of Pharmacy at the University of Toronto

Focused on Avicanna's pharmaceutical pipeline, including development and characterization through *in vitro* and *in vivo* analysis



World-Class Value Chain: Cultivation, Production and Manufacturing



2 Fully Licensed Cultivation Subsidiaries

Santa Marta Golden Hemp S.A.S. and Sativa Nativa S.A.S., both majority owned and managed subsidiaries of Avicanna

Organic and sustainable cultivation of cannabis in Santa Marta Colombia (SMGH is USDA Certified to cultivate organic hemp)

Low cost, industrial-scale cultivation infrastructure with an approximate annual capacity of 20,000 kilograms through 410,000 square feet of cultivation space


Utilizing optimal climate conditions allowing for consistent and reproducible crops



Extraction, Production, and Purification

In-house extraction and isolation infrastructure of cannabinoids in compliance with GMP and pharmaceutical standards

Joint venture with Sigma Analytics to build the first GMP quality control cannabinoid analytical laboratory and independent testing service in South America to meet Health Canada, European Pharmacopeia, US Pharmacopeia standards ("USP")



Manufacturing

Exclusive contract manufacturing agreement with Altea Farmaceutica S.A.

Pharmaceutical, phyto-therapeutic, and derma-cosmetic products manufactured in accordance with GMP certification by Health Canada, ANVISA (Brazil) and INVIMA (Colombia)

Industrial-scale production of several dosage forms, including: oil drops, creams, lotions, tablets, capsules, pellets, and chewable tablets



Product Offerings for the Global Market Place

Active Pharmaceutical Ingredients (APIs)

Aureus Offerings: CBD, THC, CBN, CBC, CBG

Consumer and Retail Products

CBD derma-cosmetics: Pura Earth Offered in retail in Colombia

Rx and Medical Products

Phytotherapeutic products: RHO Phyto Pharmaceutical products with a focus on dermatology, neurology, and pain



Colombian-based Cultivation

The Micro-climate of Santa Marta and the Foothills of the Sierra Nevada Mountains: Optimal Environmental Conditions

- Proximity to the Caribbean Sea and shipping ports
- Fertile lands, clean water, and optimal humidity levels
- 12 hours of sunlight year-round



Wind
m/s

5.5



Temp
°C

28



Rainfall
mm

545



RH
%

66



1

Sun-grown using **environmentally sustainable** practices



2

Competitive **cost advantages**, including low cost labour, land, and energy



3

Cultivated under Good Agricultural and Collection Practices (“**GACP**”)



4

Avicanna’s proprietary **extraction** and **purification** processes



5

Licenses to cultivate CBD & THC dominant strains for processing and sale in the Colombian domestic market and for export to the global market

Extraction, Production, Purification, and Manufacturing



High Quality Pharmaceutical Compliant APIs and Bulk Formulations

Utilizing proprietary extraction and purification processes in line with GMP standards and full quality controls meeting Health Canada, European Pharmacopeia, and USP standards

Product Offerings: CBD, THC, CBN, CBC, CBG

- Whole plant crude oils (60-70% purity)
- Cannabinoid distillate (80-95% purity)
- Isolated and purified cannabinoid (98-99% purity)
- Cosmetic and food grade CBD



Global GMP Certifications


- ANVISA (Brazil)
- DIGMID (Perú)
- EU
- HEALTH CANADA
- INVIMA (Colombia)

GMP Manufacturing of

- Pharmaceutical products
- Phyto-therapeutic products
- Derma-cosmetic products

Dosage Forms:

Oil drops, creams, lotions, tablets, capsules, pellets, and chewable tablets



Registered - CBD Derma-Cosmetics*

Federally registered in Colombia and currently undergoing clinical trials for derma-cosmetic formulations to support and improve the health and appearance of the skin.



BEAUTY TREATMENTS



- Anti-Aging Serum
- Anti-Aging Treatment
- Under Eye Treatment
- Dark Spot Treatment

MOISTURIZE & PROTECTION



- Skin Protecting Face Lotion (AM)
- Skin Protecting Face Lotion (PM)
- Skin Protecting Body Lotion

SPECIALIZED CARE



- Clear Skin Treatment
- Intensive Conditioning Treatment

*The product mock-ups that appear on this page are not indicative of final products that may be marketed and sold

Consumer and Retail Products



Commercialization Model:

- Cosmetics retailers
- Pharmacies OTC-Cosmetics
- Dermatology clinics
- Pura Earth and retailer e-commerce



Anti-aging Gel Serum

- Study Design: **1 arm, n=54**

End points

- Primary Endpoint:
Evaluation (visual) in the improvement of fine lines and dark spots associated with aging
- Secondary Endpoints:
viscoelasticity, hydrating Effect, TEWL, tolerability/acceptability and satisfaction

Acne-prone Skin Moisturizer

- Study Design: **1 arm, n=54**

End points

- Primary Endpoint:
Hydrating effect
- Secondary Endpoints:
Sebum production, Sensory evaluation (oily skin feeling), lesions evaluation (acne), tolerability/acceptability, QoL

Eczema-prone Skin Moisturizer

- Study Design: **1 arm, n=54**

End points

- Primary Endpoint:
Hydrating effect
- Secondary Endpoints:
viscoelasticity, skin softness, erythema, TEWL, tolerability/acceptability



Consumer and Retail Products

PRODUCT LAUNCH EXPECTATIONS*:

- Colombia
- ✓ Launched in 59 Locations (Cromantic & BLIND)
 - EU 1Q20
 - USA 1H20
 - Mexico 1H20

RHO Phyto - CBD and CBD/THC Offerings



Commercialization Model:


- Medical only - Prescription through practitioners
- Compound pharmacy - Magistral Formula
- Medical education through 120-hour CME course*
- Pharmaceutical sales approach



Organic and sustainable source of natural cannabis, formulated into cannabinoid-based phyto-therapies



USP-NF (pharmaceutical-grade) ingredients, manufactured in accordance with Health Canada and EU GMP standards



*The 120-hour CME course is still in development with Avicanna and the Universidad de Antioquia and expected to be completed by 1Q20

RHO Phyto - Canada



Distribution Model:

- Exclusive distribution agreement with Medical Cannabis by Shoppers
- Available through online portal
- Medical only
- Expected launch 1H2020



RHO Phyto - CBD and CBD/THC Offerings



Soft Gel Capsules: High Bioavailability

Designed for controlled dosage and delivery






Sublingual Spray: Rapid Onset

Sublingual formulation



Topical Cream: Local Delivery

Topical cream formulation designed for local application





Medical and Rx products

PRODUCT LAUNCH EXPECTATIONS*:

✓ USA (California) 4Q19**

- Colombia 1Q20
- Canada 1H20
 - UK 1H20
 - EU 1H20
- Australia 1H20
- Mexico 1H20


*The product launch expectations are conditional upon regulatory approvals


**Rho Phyto products were launched in California through a license agreement with the California based company LC2019 CA, Inc


Pharmaceutical Pipeline




Pharmaceutical product pipeline following the traditional drug discovery and development process for eventual submission to the applicable government agencies, such as Health Canada, FDA (United States) and INVIMA (Colombia)


-  **Dermatology**
- Epidermolysis Bullosa
 - Eczema
 - Acne
 - Psoriasis

-  **Psychiatry**
- Post-traumatic Stress Disorder (“PTSD”)
 - Anxiety and Depression
 - Sleep disorders

-  **Neurology**
- Epilepsy
 - Multiple Sclerosis
 - Parkinson’s Disease

-  **Pain**
- Chronic pain
 - Neuropathic pain
 - Localized pain

-  **Oncology**
- Palliative care

-  **Oral Health**
- Gingivitis

	Formulation Finalization	Pre-Clinical	Phase I	Phase II	Phase III	Pivotal
Dermatology						
Epidermolysis Bullosa*						
Eczema**						
Neurology						
Epilepsy						
Parkinson’s Disease						
Multiple Sclerosis						
Chronic Pain						
Neuropathic Pain**						
Arthritis						
Oncology						
Palliative Care						
Ovarian Cancer						
Psychiatry						
Anxiety						
Depression						

*Phase I studies not required for this product; pending regulatory approval
 **Pending regulatory approval

Clinical Trials



Epidermolysis Bullosa Phase II/III

Status: Submitted CTA to Health Canada August 2019

Trial Title: The Efficacy and Safety of 3% Cannabidiol (CBD) Cream in Patients with Epidermolysis Bullosa (“EB”): A Phase II/III trial

Principal Investigator: Dr. Elena Pope, MD, MSc
Co-Investigator: Dr. Irene Lara-Corrales, MD, MSc

Trial Objectives: Phase II/III study exploring the safety, tolerability, and efficacy of topical application of CBD on acute and chronic wounds affecting patients with EB

Study Design: Phase II: Open label cohort study; Phase III: Randomized, placebo controlled, blinded study, right vs left side extremity

Main Inclusion Criteria: Wounds that have not healed for over 4 weeks
Years of Age: 4-50

Study Duration: Phase II: 4 Weeks / Phase III: 8 Weeks

Centre: The study will be conducted in the specialized EB Clinic at SickKids Hospital, Toronto.

End Points:

Phase II: Tolerability (percentage of patients who experience any discomfort or, worsening that could be related to the medication), Safety (percentage of patients that needed to stop the medication as a result of an adverse event) and Target wounds’ area (percentage change of area from baseline)

Phase III: Efficacy (blister count, pain, itch, improvement in wound healing, improvement in disease state) and safety (stopped medication, adverse effects, concentration of CBD in the blood, infection in the wound)

Neuropathic Pain in Patients with Sickle Cell

Status: Ongoing Prevalence study prior to interventional study

Trial Title: Neuropathic Pain in Patients with Sickle Cell

Principal Investigator: Monika Parshad-Asnani, DM PhD
Study Director: Zachary Ramsay, MBBS

Trial Objectives: Prevalence study to determine the occurrence of neuropathic pain among Jamaicans with Sickle Cell Disease (SCD) and to conduct: Phase IIa: Interventional study with Avicanna’s proprietary sublingual tablets to measure safety, tolerability and efficacy for neuropathic pain

Study Design: Prevalence study

Main Inclusion Criteria:
Years of Age: 14+

Study Duration: 6 months

Centre: The study will be conducted in the specialized Sickle Cell division at The University of The West Indies

Patients identified with Neuropathic pain will be selected for our phase II study (clinical protocol in development)

Link to Clinical Trial

<https://clinicaltrials.gov/ct2/show/NCT04015401?term=Avicanna&rank=3>

World Class Academic and Clinical Partnerships



• University of Toronto

Dr. Christine Allen's Research Group in the Leslie Dan Faculty of Pharmacy

Research and pharmaceutical development of cannabinoid-based products through characterization, *in vitro*, and *in vivo* studies

Dr. Michael Glogauer's Lab in the Faculty of Dentistry

In vitro analysis of cannabinoid-based synergistic formulations for several oral health applications

• The Hospital for Sick Children

CTA under review with Health Canada to commence a Phase II/III clinical trial evaluating the safety and efficacy of a topical CBD isolate cream for the orphan disease Epidermolysis Bullosa

• University of Guelph

Dr. Jibrán Khokhar at the Department of Biomedical Sciences, Ontario Veterinary College

Evaluation of pharmacokinetic, pharmacological and neurobiological effect of cannabinoids in psychiatric disorders and "dual-disorder" animal models

Dr. Maxwell Jones at the Department of Plant Agriculture

Analysis of Avicanna's cultivars to provide genetic fingerprint and establish micropropagation methods for the cultivars. Additional studies include the development of polyploid plants which may be used as part of Avicanna's commercial seed production initiatives

• Universidad de Antioquia

Will include, pending approvals, a Phase I dose escalation study on oral and sublingual cannabinoid pharmaceutical products and the development and launch of a continuing medical cannabinoid education course

• Centro de Atencion e Investigacion Medica CAIMED S.A.S.

Several clinical studies including 3 Pura Earth derma-cosmetic trials and an anticipated Phase I pharmaceutical trial for a cannabinoid topical application

• University of The West Indies (UWI)

Includes a prevalence study for neuropathic pain with respect to Sickle Cell disease and a planned phase II interventional study

Patent Application and Intellectual Property



Application No.	Invention Title	Date of Filing	Status
US 62/813,817	Topical cannabinoid compositions and methods for treating skin diseases	05-Mar-19	Pending
US 62/887,158	Methods of cannabis cultivation	15-Aug-19	Pending
US 62/896,408	Oral cannabinoid compositions and methods for treating neuropathic pain	05-Sept-19	Pending
US 62/923,905	Topical cosmetic product for acne	21-Oct-19	Pending
Cosmetics	Topical cosmetic product for eczema	4Q19	Draft in progress
Cosmetics	Two different anti-aging formulations	4Q19	Draft in progress

Financial Highlights



Common Shares*: 22,364,723

- **Fully diluted: 25,903,387**
- **Free Float: 12,168,575**
- **Management Escrow: 486,669****
- **Director Escrow: 7,176,850*****
- **39 Month Escrow: 2,532,629******

Market cap: \$63.739M (CAD) – at market close on January 3rd 2020 (\$2.85 CAD)*****

Last Financing (April 2019): \$22.1M | \$8 Per Share)

Industry Peer Analysis as of January 3rd 2020

CANNABINOID PHARMACEUTICALS

GW Pharmaceuticals:

NASDAQ: GWPH | \$3.2B (USD) Market Cap

Zynerba Pharmaceuticals Inc:

NASDAQ: ZYNE | \$134.2M (USD) Market Cap

Lexaria Bioscience Corp:

LXX.CN | \$37.9M Market Cap

COLOMBIAN CULTIVATION

PharmaCielo Ltd.:

TSXV:PCLO | \$349.2M Market Cap

Khiron Life Sciences Corp:

TSXV: KHRN | \$111.1M Market Cap

Clever Leaves

(Private) | \$250M Market Cap

* Number of common shares issued and outstanding as of January 3rd, 2020.

** 10% released on January 1, 2020 and 15% to be released every six months thereafter.

*** 10% to be released on July 1, 2020 and 15% to be released every six months thereafter.

**** 10% released on October 19, 2019 and 15% to be released every six months thereafter.

***** www.bloomberg.com

Executive Management Team



Aras Azadian, M.Mgmt Chief Executive Officer

Aras brings extensive senior management experience in the biotechnology and financial sectors including his involvement in several successful start-up companies. In addition to his international experience in corporate development, his diverse roles include his previous position as the president of an investment corporation in the cannabis space and former Chief Operating Officer of an oncology company.

Setu Purohit, JD President and Chief Legal Officer

Setu is a lawyer and entrepreneur with experience in complex corporate and legal strategy, contract negotiations, and litigation. Setu has been involved in the cannabis industry for several years as an advocate for patients' rights and advising healthcare professionals, licensed cannabis producers, and other corporate and regulatory stakeholders in Canada and abroad. Prior to co-founding Avicanna, Setu operated his own private practice since 2012.

Dave Sohi, CPA, CA, CBV Chief Financial Officer

Dave received his Chartered Accountant designation in 2008, and following three years in audit and tax he joined the firm's business advisory practice as a manager. Dave's main focus in that group's practice was on mergers and acquisitions and valuation services. In 2010, Dave obtained his Chartered Business Valuator designation, and in 2013 joined Ernst and Young's Transaction Advisory Practice. Following a year with Ernst and Young, Dave opened his own practice where he provided clients with accounting and advisory services.

Dr. Amza Ali, MD, FRCP, MBA Chief Medical Officer

Dr. Ali is certified in Neurology by the Federation of Royal Colleges of Physicians of the United Kingdom, and in clinical neurophysiology by the American Board of Clinical Neurophysiology. He is the President of the Epilepsy Society of the Caribbean. Additionally, he has an MBA from Rotman and an MSc in Research Methodology at the Henley Business School in the UK. Business School in the UK.

Dr. Justin Grant, PhD, MBA EVP Scientific Affairs

Dr. Grant has over 15 years of experience in leading pharmaceutical research in sustained drug release formulations, has held academic positions at UHN and U of T and served as the research program manager of the STTARR Innovation Centre with Princess Margaret Cancer Centre UHN.

Lucas Nosiglia, MFin Chief Agricultural Officer

Lucas is a seasoned entrepreneur and executive with experience across Europe, North America and South America. Lucas has been at the forefront of Avicanna's Latin America (LATAM) operations since the company's inception in 2016. His innovative and transformative approach in navigating the cannabis industry and his former involvement in management consulting, finance and health care have been invaluable in establishing Avicanna's cultivation projects that. Lucas graduated with an Honours degree from Faculty of Economics of University of Buenos Aires and holds a Masters degree in Finance from EADA in Barcelona Spain

Janeth Mora, PharmD EVP Commercial Development

Janeth is an accomplished pharmaceuticals executive experienced in LATAM, including her tenure at INVIMA. Janeth brings executive management experience through roles in Merck and Pfizer, where she held different positions, such as Emerging Markets marketing director, as well as regulatory affairs manager in Pfizer Andean region.

Jose Beltran, MBA EVP Corporate Development

Jose offers over 30 years of pharmaceutical industry and health system executive experience across several LATAM countries with Pfizer, Abbott, Aspen and Biotoscana. Industrial engineer and marketing specialist from University of Los Andes and Program for Leadership Development (PLD24) from Harvard University.

Board of Directors

Aras Azadian, M.Mgmt
Chief Executive Officer

Setu Purohit, JD
President, Director and Chief Legal Officer

Dr. Chandrakant Panchal

Chairman

Dr. Panchal has been the Chief Executive Officer of Axcelon Biopolymers Corp. since 2008, has authored over seventy scientific papers, holds several patents in oncology, diagnostics, biopolymers and microbiology, and is an Adjunct Professor in Chemical and Biochemical Engineering at the University of Western Ontario. Dr. Panchal currently sits on the board of directors of both an oncology company known as Medicenna Therapeutics Corp. (MDNA), and Canadian Oil Recovery and Remediation Inc. (CVR) as well as Pure Global Cannabis Inc. (PURE). Dr. Panchal holds a Master of Science degree in Molecular Biology and a Ph.D. in Biochemical Engineering from the University of Western Ontario.

David Allan White

Director

Mr. White is a director and chair of audit committees of several Toronto Stock Exchange ("TSX") and NASDAQ companies. Mr. White has held several senior financial positions with John Labatt Limited, Lawson Marden Group Inc. and Laidlaw Inc. and most recently as Chief Executive Officer of TransCare Inc., a medical transportation company and as President and Chief Executive Officer of Student Transportation of America, a TSX listed company. In addition to sitting on Avicanna's Board of Directors and chairing the Corporation's audit committee, Mr. White has also been a corporate director and business consultant for FirstCall Services, a private holding company and advisory firm, since 2012. Mr. White has been a Canadian Chartered Accountant since 1978 and holds a Master of Business Administration degree from the University of Toronto.

Giancarlo Davila Char

Director

Mr. Char has experience with sustainable and organic cultivation and production of industrial scale palm oil as well as other agriculture crops such as avocados and coffee beans. In 2017, Mr. Char went on to lead a new branch of his family's business which is dedicated to producing private label oils for national distribution in supermarkets across Colombia. This business unit reached USD\$30,000,000 in sales in 2018. Mr. Char holds a Bachelor of Science in Business Administration from Northeastern University.

Janet Giesselman

Director

A Corporate Director at: Ag Growth International Inc. Omnova Solutions Inc. Twin Disc, Incorporated and at McCain Foods Limited, where she serves as Chair of the Environmental Health & Safety Committee as well as on the Audit and the Compensation and Management committees. Ms. Giesselman retired as the President and General Manager of Dow Oil & Gas, a business unit of The Dow Chemical Company, and has over 30 years of U.S. and international agriculture, energy and specialty and commodity chemicals industry experience in U.S., Europe, Latin America, the Middle East and Asia. Ms. Giesselman holds a B.Sc., Biology from Pennsylvania State University and a Masters in Plant Pathology from the University of Florida.



Senior Scientific Team

SENIOR SCIENTIFIC TEAM

Dr. Frantz Le Devedec, PhD
SVP R&D

Dr. Carlos Maldonado, MD
SVP Clinical Development

Roland Alvarez
VP, Technical Operations

Samantha Watt, MSc
VP of Scientific Affairs

Pauric Bannigan
Senior Formulation Scientist

GLOBAL SCIENTIFIC ADVISORY BOARD

Dr. Humberto Reynales, Md, PhD
CAIMED

Dr. Mauricio Torres-pradilla, Md, PhD
Fundación Universitaria De Ciencias

Dr. Hance Clarke, Md, PhD
UHN and The Toronto General Hospital

Dr. Alejandro Berlin, Md, Msc
Princess Margaret Cancer Centre

Dr. Daniel N. Sauder
John Hopkins School of Medicine

GLOBAL BUSINESS ADVISORY BOARD

Alan Friedman
Rivonian Capital

Dr. Alexis Movrammatis
ESADE Business School

Felipe Gurrero
El Grupo Daabon

Javier Hasse
Benzinga

Major Milestones



3Q19

- ✓ IPO on the TSX senior exchange as an R&D issuer
- ✓ Canadian Cannabis Research Licence issued at MaRS Discovery District, Toronto
- ✓ First export of cannabinoids for R&D purposes from Colombia to Canada
- ✓ Commencement of clinical trials on 3 Pura Earth products by CAIMED

4Q19

- ✓ Organic (USDA) certification
- ✓ Retail and e-commerce launch of Pura Earth in Colombia
- ✓ First commercial exports of CBD API's out of Colombia
- ✓ Phase 1 cultivation capacity (410,000 sq/ft) completion at both SMGH and SN in Santa Marta

Expected Upcoming Milestones*

1H20

- ✓ Agreement with Medical Cannabis by Shoppers, a subsidiary of Shoppers Drug Mart Inc., to distribute Avicanna's Rho Phyto and Pura Earth products across Canada
- Commencement of phase IIa Epidermolysis Bullosa trials at the Hospital for Sick Children in Toronto
- Retail and e-commerce launch of Pura Earth in Europe (Germany and the UK)
- Launch medical products in Colombia under the compound pharmacy model (Magistral)
- EU - GMP certification of SMGH for extraction and production of API's
- First commercial export of THC API's and THC products out of Colombia
- Completion of clinical trials on 3 Pura Earth products by CAIMED
- First commercial export of Rho Phytotherapeutics products

2H20

- Phase II expansion of SMGH and SN cultivation capacity in Santa Marta
- Expansion of Pura Earth products into tier 2 countries (Mexico, Australia, Japan, and South Africa)
- Expansion of Rho Phytotherapeutics products into Europe, Mexico, and Australia
- Completion of EB studies and commencement of phase IIa neuropathic pain studies at UWI
- Phyto-therapeutic registration of specific RHO Phyto medical products in Colombia



AVICANNA™

✉ ir@avicanna.com

☎ +1 647-243-5283